stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) Shares outstanding
Roivant Sciences Ltd.'s shares outstanding at the end of fiscal 2026 was $693.9M, unchanged from fiscal 2025. At the end of the quarter to 30 June 2026 it was $720.8M. Over the past ten years it has ranged from $51.3M (fiscal 2020) to $831.0M (fiscal 2024); the current reading is higher than 57% of that period. Roivant Sciences Ltd. ranks 5th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2026 | $693.9M | (4.35%) |
| FY2025 | $725.4M | (12.71%) |
| FY2024 | $831.0M | 16.59% |
| FY2023 | $712.8M | 6.43% |
| FY2022 | $669.8M | 6.30% |
| FY2021 | $630.0M | 1,127.21% |
| FY2020 | $51.3M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $720.8M | (11.27%) |
| Mar 2026 | $812.3M | 16.56% |
| Dec 2025 | $696.9M | 2.34% |
| Sep 2025 | $680.9M | 0.10% |
| 21 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. | $720.8M |
| GMAB Genmab A/S Sponsored ADR compare | $617.1M |
| RPRX Royalty Pharma PLC compare | $557.0M |
| BNTX BioNTech SE Sponsored ADR compare | $252.7M |
| INSM Insmed, Inc. compare | $218.8M |
| RVMD Revolution Medicines, Inc. compare | $214.9M |
| INCY Incyte Corporation compare | $203.2M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $138.0M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $115.8M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ROIV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement